Topic Listing for ViroPharma

Acceptance Appointment Successor Access Records Facilities
Accounting Auditing Matters Public Disclosure Obligations Accounting Changes Adopted
Accounting Income Taxes Accounts Receivable
Accrued Expenses Other Current Liabilities Achieves Record Net Sales Reiterates Guidance 2006
Acknowledgment Acquisition License Research Agreements
Acquisition Vancocin Pulvules Acquisition-liquidity Impact
Actions Additional Information Proposed Acquisition Lev
Additional Information Transaction Additional Information Viropharma Transaction
Adjustments Administration
Adoption 2005 Stock Option Restricted Share Plan Adoption Standards
Aggregated Option Exercises Last Year-end Values Agreed Accepted
Agreement Agreement Each Pricing Shall Governed Construed Accordance Laws
Agreement Plan Merger Agreement Sale
Air Surface Specified Allocation Supply
Alpharma Contacts Alpharma Gives Viropharma Notice
Alpharmas Invoices Alpharmas Obligations End Term
Alpharmas Representations Warranties Alpharmas Right Cease Manufacturing
Also Announces Underwriters Exercise Option Purchase Additional Notes Also Provides Timing Phase Data Disclosure Regulatory Submissions
Amended 2006 Amended 2008
Amendment Amendment 2005 Equity Incentive Plan
Amendment 2005 Stock Option Restricted Share Plan Amendment Amended Restated Certificate Incorporation
Amendment Amended Restated Certificate Incorporation Increase Number Shares Amendment Cash Bonus Plan
Amendment Confirmation Amendment Director Compensation
Amendment Distribution Manufacturing Services Agreement Amendment Employee Stock Purchase Plan
Amendment Number Security Agreement Amendment Plan
Amendment Rights Agreement Amendment Termination
Amendment Vesting Provisions Certain Options Amendments
Amendments Consent Holders Amendments Without Consent Holders
Annex Annual Meeting
Annual Meeting Stockholders Annual Meeting Stockholders 2009
Annual Routine Pulls Minimum Lot Each Strength Per Another Oral Glycopeptide Solution Not Been Shown Bioequivalent
Antiviral Activity Maribavir Measured Reductions Cmv Reactivation Antiviral Activity Results
Applicable Law Application Funds
Appoints Charles Rowland Chief Financial Officer Approval Plan
Arbitration Assistance Questions
Attend Meeting Order Vote Audit Committee
Audit Expenses Audit Record Creation Retention
Availability Suboptimally Performing Generic Version Vancocin Capsules Enhance Available Information
Aventis Termination Agreement Background
Base Salary Incentive Plan Cash Bonus Proportion Total Basis Presentation
Because Target Patient Population Cinryze Small Not Been Beneficial Ownership Reporting Compliance
Benefits Agreement Biren Amin Stanford Group Analyst
Board Directors Bone Marrow Transplant Patients
Breach Remedies Brian Rye Janney Montgomery Analyst
Brian Scorning Sig Analyst Business Activities
Business Development Business Development Activities
Business Development Highlights Business Developments
Calls Additional Scientific Data Withdrawal Guidance Capital Resources
Cash Equivalents Cash Highlights
Cdi Program Certain Duties Responsibilities
Certain Relationships Related Transactions Certain Rights Agent
Certain Transactions Certificate Registration Transfer Change Address
Certification Change Control
Change Control Agreements Severance Agreement Plan Change Control Agreements Severance Plan
Change Definition Good Reason Change Fair Value Derivative Liability
Change Vote After Return Proxy Card Changes Internal Control Over Financial Reporting
Changes Product Specifications Charges Earnings Resulting Application Accounting Methods Adversely Affect
Check Appropriate Box Below Form 8-k Filing Intended Choice Law
Cinryze Cinryze Derived Human Plasma Therefore Subject Risk Biological
Cinryze Esterase Inhibitor Human Cinryze Inhibitor Human
Cinryze Regulatory Status Cinryze Treat Acute Attacks Hereditary Angioedema
Class Director Leaving Board 2006 Class I-directors Terms Continuing Until 2006
Class I-directors Terms Continuing Until 2009 Class I-nominees Terms Continuing Until 2009
Class I-nominees Terms Continuing Until 2012 Class Ii-directors Terms Continuing Until 2007
Class Ii-directors Terms Continuing Until 2010 Class Ii-nominees Terms Continuing Until 2010
Class Iii-director Term Continuing Until 2008 Class Iii-director Term Continuing Until 2011
Class Iii-directors Terms Continuing Until 2011 Class Iii-nominee Term Continuing Until 2008
Clinical Clinical Pipeline
Clinical Results Clinical Study Design Generic Versions Vancocin Consistent Requirements
Clinical Trial Description Closing Procedure
Clostridium Difficile Clostridium Difficile Infection Cdi
Cmv Cmv Program
Code Business Conduct Ethics Code Ethics
Colin Broom Viropharma Chief Scientific Officer Collaborations
Commercial Supply Commercialization Strategy
Commercially Reasonable Efforts Commitments Contingencies
Committees Committees Meetings Board
Common Cold Asthma Exacerbations Program Common Stock
Companies Host Conference Call 1030 Eastern Today Discuss Companies Preparing Initiate Phase Clinical Evaluation
Comparative Clinical Trials Necessary Establish Bioequivalence Generic Versions Compensation
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Directors Competition
Competition Fair Dealing Compliance Laws
Comprehensive Income Comprehensive Income Loss
Concentration Credit Risk Conclusion
Condition Results Operations Conditions Issuance Shares
Conditions Precedent Obligations Consummate Conduct Business Pending Consummation
Conference Call 1000 Today Discuss Results Conference Call Webcast
Conference Call Webcast Information Confidential
Confidentiality Confidentiality Inventions Agreements
Conflicts Interest Consent Independent Registered Public Accounting Firm
Consolidate Etc Consolidated Balance Sheets
Consolidated Statements Comprehensive Income Loss Contents
Contingent Value Rights Agreement Continuing Operations
Contract Interpretation Contracts
Contractual Obligations Control Number
Control Persons Controls Procedures
Convertible Hedge Warrant Transactions Affect Value Senior Notes Convertible Notes Registration Rights Agreement
Convertible Subordinated Notes Core Development Programs
Core Patent Protection Vancocin Expired Result Significant Competition Corporate Governance
Cost Sales Cost Sales Excluding Amortization Product Rights
Cost Sales Gross Margin Cost Sales Gross Product Margin
Counterparts Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Policies Current Credit Financial Market Conditions Exacerbate Certain Risks
Current Report Current Treatments Hae
Currently Depend Future Continue Parties Manufacture Products Including Currently Depend Future Parties Manufacture Products Product Candidates
Customers Cytomegalovirus
Cytomegalovirus Glaxosmithkline Cytomegalovirus Viremia Disease Indication
Debarment Debt Highlights
Debt Reductions Debt Service Requirements
Deductibility Certain Compensation Default
Definitions Delivery Risk Loss
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Depend Collaborations Parties Reduce Product Revenues Restrict Ability Depend Key Personnel Not Able Retain Employees Recruit
Depend Single Manufacturers Certain Components Used Vancocin Cinryze Description Stock Purchase Plan
Development Development Activities
Development Activity Costs Development Lots Validation Stability
Development Plan Development Programs
Development Validation Stability Charges Difficile Infection
Difficile Infection Cdi Direct Compensation Actions Chief Executive Officer Other Named
Direct Expenses Development Programs Direct Expenses-core Development Programs
Direct Expenses-development Programs Direct Expenses-non-core Development Programs
Direct Expenses-non-core Development Programs Active Direct-core Programs
Direct-non-core Programs Director Compensation Policy
Director Nominations Director Summary Compensation Table
Directors Executive Officers Registrant Disclaimer
Disclosure Notice Disposition Shares
Distribution Commercial Products Dependent Limited Number Party Service Dividend Equivalents
Documents Incorporated Reference Due 2017
Earnings Loss Per Share Earnings Per Share
Effect Amendments Effect Headings
Effective Date Eld 2005
Eld 2006 Eld 2008
Eld 2009 Eld Une 2007
Election Class Director Election Class Directors
Elements Compensation Eligibility Participation
Employee Invention Non-disclosure Agreement Employee Retirement Income Security Act 1974 Amended
Employee Savings Plan Employee Stock Option Plans
Employee Stock Purchase Plan Employees
Enforcing Participants Rights Entire Agreement
Entitled Vote Annual Meeting Entry Material Definitive Agreement
Equipment Equipment Leasehold Improvements
Equity Compensation Plans Equity Financing
Equity Incentive Plan Equity Investment
Establishing Vitro-in Vivo Correlations Ivivc Extremely Difficult Never Estimates
Ethical Conduct Evaluation Disclosure Controls Procedures
Even After Receive Regulatory Approval Vancocin Fail Comply Even After Regulatory Approval Received Vancocin Cinryze Fail
Even After Regulatory Approval Received Vancocin Fail Comply Even Successful Integrating Vancocin Dependent Ability Raise Financing
Even Successful Maintaining Increasing Vancocin Revenues Dependent Ability Event Date Time Jul 2008 1030am
Event Merger Completed Incur Significant Additional Expenses Connection Exact Name Registrant Specified Charter
Exchange Shares Executed Copy
Execution Amendments Execution Copy
Execution Counterparts Executive Compensation
Executive Officers Executive Salaries
Executive Summary Exempt Positions
Exercise Options Exhibits
Exit Disposal Activities Expansion Severance Protection Period
Expenses Expenses Advance Clinical Programs Support Vancocin Growth
Exton 19341 Face Costs Risks Associated Compliance 404 Sarbanes-oxley Act
Fail Comply Obligations Agreements License Development Commercialization Rights Fail Comply Regulatory Requirements Experience Unanticipated Problems Approved
Fair Value Measurement Fda Determined Vivo Data Failed Demonstrate Oral Vancomycin
Fda Guidance Bioequivalence Requirements Locally-acting Drugs Fully Supports Fdas Acps Consider Comparative Clinical Trials Only Adequate
Federal Income Tax Consequences Awards Granted 2005 Plan Federal Trade
Figure Chromatogram Vancomycin Hcl Commercial Sample Purified Figure Comparative Vitro Dissolution Profiles Various Mesalalmine Formulations
Figure Comparison Infectious Diseases Society America Emerging Infections Figure Mean Plasma Serum Concentrations Healthy Fasting Volunteers
Figure National Estimates Short-stay Hospital Discharges Clostridium Difficile Figure Solubility Vancomycin Hydrochloride Determined Shake Flask Method
Financial Financial Highlights
Financial Instruments Financial Results
Financial Statements Business Acquired Financial Statements Exhibits
Financial Statements Pro Forma Information Exhibits Financing
Focus Pipeline Advancement Camvia Momentum Building Toward 2009 Force Majeure
Forecasting Forecasts Orders Shipping
Foregoing Accordance Understanding Please Sign Return Counterparts Hereof Foreign Operations
Forfeiture Option Form 10-k
Form 10-q Form Comfort Letter
Form Designated Shares Form Opinion Pepper Hamilton
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Freedom Information Act Request
Fundamental Change Purchase Feature Senior Convertible Notes Delay Funding Especially Terms Acceptable Not Available Meet Future
Future Product Revenues Sales Vancocin Cinryze Reduced Imports Future Product Revenues Sales Vancocin Reduced Imports Countries
Future Products Not Accepted Market Harm Business Results Future Sales Common Stock Public Market Adversely Affect
Future Sales Common Stock Public Market Conversion Senior Future Sales Common Stock Public Market Issuances Pursuant
Gain Sale Biodefense Assets Net Gain Sale Short Term Investments
General Information General Provisions
Genetic Sequencing Get Additional Information
Glaxosmithkline Agreement Goodwill Impairment
Goodwill Intangible Assets Governing Law
Governing Law His Confirmation Shall Governed Laws State Governing Law Termination Agreement Shall Governed Laws State
Government Other Regulations Granting Options
Hcv Program Hcv-796
Held 2005 Held 2006
Held 2007 Held 2008
Held 2009 Hepatitis
Hepatitis Virus Levels Hepatitis Wyeth
Hereditary Angioedema Hereditary Angioedema Hae
Highlighted Cinryze Inhibitor Human Commercial Launch Highlighted Record Vancocin Sales Increase Net Guidance
Historically Vancocin Been Subject Limitations Amount Payment Reimbursement History Losses Future Profitability Uncertain
Holders Dividends Host Conference Call 1000 Today
Host Conference Call Discuss Clinical Results 900 Tomorrow Householding Annual Meeting Materials
Http Wwwregulationsgov Fdmspublic Component Mainmaindocumentdetailo090000648069607c Human Resources
Hydrochloride Products Iaw Agreement
Immediate Release Impairment Disposal Long-lived Assets
Impairment Loss Important Information Forward-looking Statements
Incentive Stock Option Agreement Incentive Stock Options
Income Tax Benefit Income Tax Expense
Income Taxes Increased Indebtedness Result Offering Harm Financial Condition Results
Increased Indebtedness Result Senior Convertible Notes Issuance Harm Increased Severance Payments Benefits Covered Termination
Increases Full Guidance 2008 Indebtedness Debt Service Payments Negatively Impact Liquidity
Indebtedness Other Financial Obligations Harm Condition Results Operations Indemnification
Indemnification Remedies Independent Contractor
Independent Public Accountants Independent Public Accounting Firm
Independent Registered Public Accountants Independent Registered Public Accounting Firm Fees Services
Index Index Consolidated Financial Statements
Index Exhibits Indirect Development Discovery Expenses
Indirect Expenses Infinium Announces Ogds New Bioequivalence Standard Vancocin
Information Property Rights Obligations Initial Investors Purchase Additional 125 Aggregate Principle Amount-
Insider Trading Insurance
Intangible Amortization Intangible Amortization Acquisition Technology Rights
Intangible Assets Integrated Agreement
Intellectual Property Intellectual Property Rights
Interest Interest Expense
Interest Income Interest Other Expenses Gains
Intermediate Supply Agreement Intermediate Supply Agreement Biotest
International Meeting Hepatitis Virus Related Viruses Intra-gastric Patient Population Cdad Higher Healthy Subjects Vancocin
Introduction Inventories
Inventory Investigation
Iro Harma Ncorporated Issuance 10350000 Shares Common Stock
Issuance Common Stock Connection Merger Decrease Market Price Issuance Cvrs
Jason Kolbert Sig Analyst Joinder
Josh Schein Lev Pharmaceuticals Ceo Late Charges Undisputed Amount Due Not Paid Before
Lease Lease Costs
Lease Termination Agreement Legal Holidays
Legal Proceedings Lev Pharmaceuticals Inc
Lev Pharmaceuticals Inc Acquisition Lev Safe Harbor Statement
Lev Stockholders Sell Common Stock Received Merger They Lev Stockholders Sell Viropharma Common Stock Received Consideration
Lev Stockholders Sell Viropharma Common Stock Received Merger Licensed Technology
Licensors Not Protect Rights License Agreements Them Reasonably Limited Sales Marketing Infrastructure Unable Develop Own Capability
Liquidity List Holders
Litigation Liver Phase Study Design
Liver Transplant Patients Long-term Debt
Long-term Success Depends Ability Develop Receive Regulatory Approval Looking Ahead 2005
Looking Ahead 2006 Looking Ahead 2007
Looking Ahead 2008 Looking Ahead 2009
Loss Bond Redemption Management Report Internal Control Over Financial Reporting
Manner Converting Shares Manufacture Purchase
Manufacturers Unable Obtain Raw Intermediate Materials Needed Manufacture Manufacturing
Manufacturing Distribution Manufacturing Price
Manufacturing Relationship Document Mrd Maribavir
Marked Record Revenue Growth Strong Clinical Momentum Market Information
Market Price Common Stock Decline Result Merger Marketed Products
Marketing General Administrative Activities Marketing General Administrative Expenses
Marketing Sales Master Agreement
Material Modification Rights Security Holders Materials
Members Board Directors Memorandum Lease Termination Notice
Memorandum Purchase Option Termination Notice Merger Agreement
Merger Subject Closing Conditions Result Completion Being Delayed Miscellaneous
Modification Extension Renewal Award Name Person Filing Proxy Statement Other Registrant
Names Addresses Representatives Narrows 2009 Cinryze Net Sales Guidance
Negotiation Arbitration Net Gain Bond Repurchase
Net Gain Loss Bond Redemption Net Loss Gain Bond Redemption
Net Sales Cinryze Esterase Inhibitor Human New Accounting Standards
Next Steps Non-alienation
Non-core Development Programs Non-employee Stock Options
Non-exempt Positions Non-gaap Disclosures
Non-gaap Financial Measures Non-qualified Stock Option Agreement
Non-qualified Stock Options Non-solicitation Non-competition Clauses
Non-toxigenic Difficile Nontransferable
Not Able Pay Debt Other Obligations Not Know Whether Vancocin Continue Competitive Markets Serves
Not Patent Protection Composition Cinryze Rely Exclusivity Provided Not Receive Fda Approval Cinryze Acute Treatment Hae
Not Successful Integrating Lev Business Then Benefits Acquisition Not Successfully Integrate Lev Business Then Benefits Merger
Not Sufficient Funds Purchase Senior Convertible Notes Repurchase Notice
Notice Annual Meeting Proxy Statement 2007 Report Notice Annual Meeting Proxy Statement 2008 Report
Notice Holders Notices
Notices Rights Agent Buyer Number 000-21699
Objectives Compensation Off-balance Sheet Arrangements
Offering Officers
Ogd Communications Indicating Clinical Studies Longer Required Only Inhibitor Therapy Approved Prevent Potentially Fatal Condition
Operating Cash Inflows Operating Cash Outflows
Operating Highlights Operating Results
Operational Operations
Operations Prior Closing Ops
Option Exercises Stock Vested Option Grants Last
Orderly Sale Agreement Orders
Orders Vancocin Fluctuate Depending Inventory Levels Held Major Orders Vancocin Increase Decrease Depending Inventory Levels Held
Organization Business Activities Osg Norwich Pharmaceuticals Inc
Osg Supplied Materials Other
Other Agreements Other Agreements Parties
Other Covenants Agreements Other Entities Seek Establish Collaborative Arrangements Product Research
Other Events Other Expenses Issuance Distribution
Other Income Expense Other Matters
Other Provisions Overall Cash Flows
Overview Overview Dissolution Testing
Part Part Ii-other Information
Part Other Information Participation
Particulars Parties
Patents Proprietary Technology Pathological Changes Variability Gastrointestinal Motility Associated Cdad Negate
Patient Labeling Self Administration Patients On-therapy
Payment Payment Cvr Amount
Payment Procedures Payments Relationships Healthcare Professionals Government Personnel
Payroll Deductions Pdufa Date Cinryze Acute Hae Indication 2009
Peer Group Data Pendency Merger Not Able Enter Certain Business Combinations
Performance Graph Personal Responsibility
Petition Stay Action Phase Clinical Trial Description
Phase Clinical Trial Design Phase Combination Data Highlight Favorable Tolerability Additive Antiviral
Phase Preliminary Antiviral Data Picornavirus Common Cold Program
Picornaviruses Picornaviruses Sanofi-aventis
Picornaviruses Schering-plough Plan
Plan Contributions Not Affect Employment Plasma
Pleconaril Schering-plough Corporation Policy Pre-approval Audit Non-audit Services
Post-approval Costs Potential Competitors Greater Resources Experience Develop Products Technologies
Potential Competitors Respect Product Candidates Development Develop Products Power Attorney
Preamble Preferred Stock
Prescribed Clauses Presentation
Previously Used Hazardous Materials Business Claims Relating Improper Price
Pricing Pricing Agreement
Principal Amount Senior Convertible Notes Principles Consolidation
Pro Forma Condensed Consolidated Financial Information Pro Forma Financial Information
Procedures Submitting Confidential Anonymous Complaints Regarding Accounting Regulatory Process
Product Means Vancomycin Hcl Specifications Identified Attached Agreement Product Pipeline
Product Specifications Product Specifications Means Identified Attached Agreement
Product Vancocin Capsules Materials Promissory
Promoted Chief Operating Officer Property Equipment Building Improvements
Property Plant Equipment Prophylaxis Against Hereditary Angioedema
Proposed Elements Clinical Study Evaluate Generic Versions Vancocin Prospectus Supplement Dated 2005
Provided Osg Norwich Provides 2009 Cinryze Net Sales Guidance
Proxy Solicitation Prudent Actions Plan Fiduciaries
Public Accounting Firm Publicity Nondisclosure
Purchase Agreement Plasma Centers America Llc Purchase Investment Other Restrictions
Purchase Sale Purpose
Pursuant Requirements Securities Exchange Act 1934 Registrant Duly Pursuant Requirements Securities Exchange Act 1934 Report Been
Quality Agreement Quality Agreement Being Intention Amended Restated Signed Within
Quality Agreement Means Document Attached Hereto Sets Out Quantitative Qualitative Disclosures Market Risk
Question Answer Ratification Appointment Kpmg Independent Registered Public Accounting Firm
Recalls Recent Transactions
Recently Issued Accounting Pronouncements Recitals
Reclassification Reconciliation Gaap Net Income Adjusted
Record-keeping Records
Reference Standard Management Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 610-458-7300 Regulation Disclosure
Regulatory Process Expensive Time Consuming Uncertain Prevent Obtaining Reiterates Full Vancocin Sales Guidance
Release Non-disparagement Agreement Relocation Expenses
Rely Employees Consultants Contractors Suppliers Manufacturers Collaborators Keep Rely Employees Consultants Keep Trade Secrets Confidential
Rely Party Perform Distribution Logistics Services Vancocin Rely Single Party Perform Distribution Logistics Services Vancocin
Remainder Page Intentionally Left Blank Report Audit Committee
Report Compensation Committee Report Independent Registered Public Accounting Firm
Reporting Investigation Procedures Reports 2004 Financial Results 2005 Guidance
Reports 2005 Financial Results Provides Guidance Reports 2007 Financial Results
Reports Full 2006 Financial Results Reiterates Guidance Reports Record Revenue Increases Guidance 2005
Representations Warranties Representations Warranties Osg
Representations Warranties Seller Representations Warranties Viropharma
Requirement Clinical Studies Research Development Expenses
Reservation Shares Resignation Removal Appointment Successor
Resolutions Governing Nominating Committee Respect Vitro Dissolution Testing Binding Assays Fdas Background
Restricted Common Stock Restricted Stock Units
Restructuring Restructuring Plan Not Achieve Intended Benefits
Restructuring Transition Activities Results
Results Financial Operations Condition Revenue
Revenue Recognition Revenue-grant Other Revenue
Revenue-license Fee Milestone Revenue Revenue-license Fee Milestone Revenues
Revenue-vancocin Cinryze Product Sales Revenue-vancocin Product Sales
Revenues Review Approval Ratification Transactions Related Persons
Right Exercise Option Shall Vest Exercisable Follows Vesting Rights Been Future Granted Holders Common Preferred Stock
Rights Lose Right Develop Manufacture Market Sell Products Risk Factors
Risks Associated International Business Relationships Materially Adversely Affect Roberts Viropharma Corporate Communications
Role Consultants Routine Pulls Each Strength Per Total
Rules Arbitration Forum Claim Filed Amendments Thereto Shall Safety Tolerability Results
Salary Increases Sales Allowances
Sales Mainly Limited Number Pharmaceutical Wholesalers Changes Terms Sanofi-aventis Agreement
Sarbanes-oxley Act 2002 Schedule
Schedule Covenants Guarantor Schedule Exceptions
Schedule Part Deeds Documents Affecting Premises Schedule Part Exceptions Reservations
Schedule Part Rights Easements Granted Schering Plough Agreement
Scientific Clinical Evidence Invalidates Ogds Approach Generic Product Scientific Integrity
Scientific Supplement Also Filed Scope
Sct Phase Study Design Securities Purchase Agreement
Securities Registered Pursuant Act Security Ownership Certain Beneficial Owners Management
Segment Information Selected Consolidated Balance Sheet Data
Selected Financial Information Self-administration
Selling General Administrative Expenses Senior Convertible Notes
Senior Notes Separation Agreement Joshua Tarnoff Former Chief Commercial Officer
Separation Agreement Release Service Charge Exclusions
Severability Severability Clause
Severance Agreement Chief Executive Officer Severance Pay Plan
Share-based Compensation Share-based Payments
Shares Shares Entitled Vote Present Conduct Business Annual Meeting
Shares Per Offering Shipment Alpharma Fax Following Documents Viropharma
Shipping Shipping Instructions Terms Shall Set Forth
Short-term Investments Siga Agreement
Signature Page Follow Signature Pages Follow
Signatures Signatures Contained Following Page
Significant Indebtedness Debt Service Payments Negatively Impact Liquidity Single Source Supplier
Specification Products Specification Vancomycin Hcl Usp
Specified Purchase Order Stability Costs
Stability Costs Following Commercial Manufacturing Initiation Statement Cash Flows
Statute Regulation Requires Scientifically Reasonable Adequate Demonstration Bioequivalence Stephen Willey Thomas Weisel Analyst
Stock Stock Compensation
Stock Delisted Nasdaq National Market Then Become Subject Stock Option Grants
Stock Options Stock Price Continue Volatile
Stock Subject Plan Stock-based Compensation
Stockholder Meeting Held 2009 Stockholder Proposals-for 2005 Annual Meeting
Stockholder Proposals-for 2006 Annual Meeting Stockholder Proposals-for 2008 Annual Meeting
Stockholder Voting Agreement Stockholders Equity
Strategic Direction Strategic Plan Not Achieve Intended Results
Strategic Relationships Strategic Risks Uncertainties
Study Design Subject Product Liability Claims Expensive Difficult Defend Result
Submission Matters Vote Security Holders Subordinated Convertible Notes
Subordinated Notes Due 2007 Subsequent Event
Subsequent Events Subsidiaries
Substantial Amount Intangible Assets Required Write Down Adjust Successful Commercialization Product Candidates Depend Part Availability Adequacy
Successful Commercialization Products Depend Part Availability Adequacy Party Successful Commercialization Products Depend Part Availability Party Reimbursement
Succession Assignment Delegation Successor Substituted
Successors Successors Assigns
Such Forbearance Enforce Agreement Arbitrate Shall Not Constitute Summary Compensation Table
Supplemental Cash Flow Information Supplemental Indenture Number
Supplier Relationship Supplies Human Plasma Interrupted Unable Acquire Adequate Meet
Supply Chain Vancocin Supply Finished Products Interrupted Ability Maintain Inventory Levels
Survey Data Survival
Tab Table Contents
Table Dissolution 250 Vancocin Capsules Performed Using Usp Target Disclosure Memorandum
Tax Accounting Considerations Executive Compensation Taxes
Taxes Fees Expenses Withholding Term Termination
Termination Termination Material Definitive Agreement
Terms Conditions Options Terms Conditions Restricted Shares
Terms Merger Threatening Disease
Time Award Time Periods Patient Demand Approaches Manufacturing Capacity Manage
Title Title Each Class
Tolerability Maribavir Touch-tone Telephone
Transaction Terms Transactions Related Persons
Transactions Terms Merger Transferability
Trial Description Unable Obtain Reimbursement Cinryze Government Health Administration Authorities
Unable Retain Key Viropharma Lev Personnel After Merger Unable Successfully Commercialize Cinryze Significantly Delayed Limited Doing
Uncertainty Regarding Merger Effects Cause Customers Suppliers Strategic United States
United States Experiencing Emerging Clostridium Difficile -associated Disease Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Validation Lots
Validation Lots Capital Reimbursement Valuation Techniques Cash Equivalents Measured Fair Value Using
Vancocin Vancocin Acquisition
Vancocin Capsules Vancocin Capsules Contain Complex Biologically-derived Antibiotic Peptide Unique
Vancocin Capsules Lilly Vancocin Capsules Not Rapidly Dissolving Asserted Ogd Application
Vancocin Capsules Only Fda Approved Treatment Cdad Considered Vancocin Capsules-amended Manufacturing Agreement
Vancocin Capsules-contingent Consideration Vancocin Pulvules
Vancocin Pulvules Net Sales Guidance Vancomycin Cannot Considered Highly Soluble Luminal Environment Patients
Variability Associated Dissolution Testing Complicates Extrapolation Vivo Product Via Hand Delivery
Via Mail Violations Code
Viropharma Announces Changes Board Directors Viropharma Announces Data Hcv-086 Proof Concept Study
Viropharma Announces Discontinuation Hcv-796 Development Viropharma Announces Presentation Hcv-796 Phase Data Digestive Disease
Viropharma Board Compensation Policy Viropharma Comments Vancocin
Viropharma Contacts Viropharma Forward Looking Statement
Viropharma Forward-looking Statements Viropharma Further Comments Vancocin
Viropharma Gives Alpharma Notice Viropharma Incorporated
Viropharma Incorporated Prices Public Offering Common Stock Viropharma Leading Experts Voiced Concern Process Developing Bioequivalence
Viropharma Provides Update Vancocin Viropharma Stockholders Vote Approve Debt Exchange
Viropharma Supplied Materials Viropharmas General Rights Obligations
Viropharmas Obligations End Term Viropharmas Representations Warranties
Viropharmas Rights Obligations Vitro Media Recommended Dissolution Testing Not Adequately Simulate
Vote Required Approval Vote Today Ways
Voting Dividends Interest Equity Ownership Buyer Waiver
Waivers Code Business Conduct Ethics What Purpose Annual Meeting
What Recommendations Board Directors What Shares Held Street Name
What Vote Required Approve Each Withdrawals
Witnesseth Working Capital Highlights
Wyeth Wyeth Agreement
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki